National Pharmaceutical Pricing Authority Sets Price Limits on 39 Medications for Conditions from Hypertension to Diabetes

The National Pharmaceutical Pricing Authority (NPPA) has established a ceiling on the retail prices of 39 medicines. The regulatory body has maintained prices for various drugs, including those utilized in treating hypertension, diabetes, and heart disease, among others.

National Pharmaceutical Pricing Authority (NPPA) has established a ceiling on retail prices of 39 medicines, including those for hypertension, diabetes, heart disease, etc pic.twitter.com/jc4CVUIx8c

— CNBC-TV18 (@CNBCTV18Live) July 11, 2026

In the official notification, the Ministry of Chemicals and Fertilisers indicated that manufacturers of formulations or “new dry” under the DPCO, 2013, must set retail prices that do not exceed the established maximum.
 

 

 

Moreover, the announcement stated that any other existing manufacturer introducing the same new drug within twelve months of this notification’s publication in the Official Gazette is allowed to do so at a retail price not surpassing the specified amount.

Among the drugs featured in the list are Tenecteplase (TNK-TPA) Injection, Combikit Darunavir, Ritonavir & Dolutegravir Tablets, Amoxicillin, Aspirin, and Potassium Clavulanate Dispersible Tablets, among others.

Also Read: Retail prices capped for 42 medicines, including anti-diabetic drugs and antibiotic formulations

This action follows a recent similar initiative where the NPPA capped retail prices for 42 drug formulations. This decision, made in May by the National Pharmaceutical Pricing Authority (NPPA), was in accordance with the Drugs Prices Control Order (DPCO), as detailed in a notification issued by the Ministry of Chemicals and Fertilisers.